Bolligen, Switzerland

Matthias Ehrsam

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Roche Diagnostics International Ag, Roche Diagnostics Operations, Inc.. Active years: 2013-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Ehrsam. Retrieved from https://idiyas.com/inventor/matthias-ehrsam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 50.0

 

Average Co-Inventor Count = 5.3

ph-index = 1

Forward Citations = 126(Granted Patents)


Company Filing History:


Years Active: 2013-2014

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Matthias Ehrsam: A Profile of Innovation

Introduction

Matthias Ehrsam is an inventor based in Bollingen, Switzerland. He has made significant contributions to the field of diagnostics through his work with prominent companies. Although he holds no patents, his experience in the industry is noteworthy.

Latest Patents

Matthias Ehrsam currently has 2 patents. Despite this, his expertise and knowledge in the field of diagnostics are valuable assets.

Career Highlights

Ehrsam has worked with Roche Diagnostics GmbH and F. Hoffmann-La Roche AG, two leading companies in the healthcare sector. His roles in these organizations have allowed him to develop a deep understanding of diagnostic technologies and their applications.

Collaborations

One of his notable coworkers is Markus Oberli. Their collaboration has likely contributed to advancements in their respective fields.

Conclusion

Matthias Ehrsam's career reflects a commitment to innovation in diagnostics, even in the absence of patents. His work with leading companies showcases his expertise and dedication to the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…